UPDATE:
An earlier version of this story depended on Rox Medical’s website and SEC filings for information. But CEO Rodney Brenneman, who returned a call after the story was published, said those were not fully accurate.
Name of Company: Rox Medical Inc.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Industry: Medical devices
Location: San Clemente, California
Solution/Product: Rox Flow proedure, which places an implanted device delivered via a catheter for patients suffering from uncontrolled hypertension.
Money Raised: $6 million, according to CEO Rodney Brenneman; company has raised $53.1 million, excluding this round, since 2004.
How it will be used: To fund a randomized trial called CONTROL-HTN of 100 patients outside the U.S.
Investors: Versant Ventures Domain Associates (previous investors: Essex Woodland and Prism VentureWorks
Management team: Rodney Brenneman, President & CEO; Chris Yelley, Director of Operations; Peter Balmforth, Director of Sales and Clinical Support, Europe
Market size: Same as or slightly larger than the renal denervation market, said Brenneman. The renal denervation market has the potential to be a $2.9 billion market by 2021, according to Millennium Research Group.
[Photo Credit: freedigitalphotos user Salvatore Vuono]